/Regeneron%20Pharmaceuticals%20logo%20is%20seen%20on%20a%20screen%20and%20a%20hand%20holding%20pills_%20By%20Rafael%20Henrique.jpeg)
Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company has a market capitalization of $82.3 billion and develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases, as well as cancer and more.
Companies with a market cap of $10 billion or more are typically referred to as “large-cap stocks.” REGN fits squarely into that category, with its market cap exceeding this threshold and reflecting its substantial size and influence in the biotechnology industry.
However, the stock currently trades 37.1% below its 52-week high of $847 recorded on Aug. 21. REGN has surged 37.2% over the past three months, outperforming the State Street Healthcare Select Sector SPDR ETF’s (XLV) 16.1% rise during the same time frame.
In the longer term, REGN has delivered a similar performance. The stock has grown 41.9% over the past 52 weeks, outperforming the 24.9% surge of XLV over the same period. REGN has been trading above its 200-day and 50-day moving averages since July, indicating bullish momentum.
On July 30, REGN stock rose 6.2% following the release of its better-than-expected Q2 2026 earnings. The company’s revenue for the quarter rose 16.7% from the prior year’s quarter to $4.3 billion and surpassed the Street’s forecasts. Management attributed this growth to continued momentum for key products, such as Dupixent, EYLEA HD, and Libtayo, helping the company to reach new sales highs. Additionally, its adjusted EPS amounted to $14.29, also topping Wall Street’s estimates.
When stacked against its rival, Vertex Pharmaceuticals Incorporated (VRTX) has surged 40.1% over the past year, lagging behind REGN.
Wall Street has a moderately optimistic view of the stock currently. Among the 29 analysts tracking REGN, the overall consensus stands at a “Moderate Buy.” Its mean price target of $852.18 suggests a 3.4% upside potential from current price levels.
On the date of publication, Aritra Gangopadhyay did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
/A%20close-up%20shot%20of%20a%20Broadcom%20chip%20by%20g0d4ather%20via%20Adobe%20Stock.jpeg)
/A%20close-up%20of%20a%20SpaceX%20sign%20by%20Sundry%20Photography%20via%20Adobe%20Stock.jpeg)
/NVIDIA%20Corp%20video%20chip-by%20Antonio%20Bordunovi%20via%20iStock.jpg)
